KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Income (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Operating Income for 7 consecutive years, with $33.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 2091.55% year-over-year to $33.2 million, compared with a TTM value of $104.9 million through Dec 2025, up 2338.4%, and an annual FY2025 reading of $104.9 million, up 6386.04% over the prior year.
  • Operating Income was $33.2 million for Q4 2025 at Aurinia Pharmaceuticals, up from $29.7 million in the prior quarter.
  • Across five years, Operating Income topped out at $33.2 million in Q4 2025 and bottomed at -$50.5 million in Q1 2021.
  • Average Operating Income over 5 years is -$14.2 million, with a median of -$16.2 million recorded in 2023.
  • The sharpest move saw Operating Income crashed 86.78% in 2021, then soared 2091.55% in 2025.
  • Year by year, Operating Income stood at -$32.7 million in 2021, then increased by 14.08% to -$28.1 million in 2022, then decreased by 5.6% to -$29.7 million in 2023, then skyrocketed by 94.38% to -$1.7 million in 2024, then skyrocketed by 2091.55% to $33.2 million in 2025.
  • Business Quant data shows Operating Income for AUPH at $33.2 million in Q4 2025, $29.7 million in Q3 2025, and $20.1 million in Q2 2025.